Vitreoretinal amyloidosis is believed to be associated universally withmutations in the genes encoding transthyretin and found exclusively as partof the familial amyloidotic polyneuropathy (FAP) syndrome.1 Wedescribe herein an unusual case of biopsy-proved vitreoretinal amyloidosiswithout systemic involvement and demonstrate that vitreoretinal amyloidosiscan occur with intact wild-type transthyretin genes.
A 70-year-old woman with a history of hypercholesterolemia, chronicobstructive pulmonary disease, a distant cerebrovascular accident, and bilateralcataract extractions was first seen by us with "black snow" clouding her visionin both eyes. Review of systems was otherwise unremarkable, and her familyhistory was negative for amyloidosis. Her visual acuity was 20/50 OD and 20/60OS and worsened with pinhole examination. There was no relative afferent pupillarydefect, intraocular tensions were within normal limits, and slitlamp examinationdisclosed quiet anterior segments and clear well-centered posterior chamberintraocular lens implants bilaterally. Dilated fundus examination showed multiple,white, refractile vitreous opacities dispersed in a syneretic vitreous inboth eyes (Figure 1A). Yellow depositswere also seen deep to the retina in the periphery (Figure 1B). A therapeutic and diagnostic left vitrectomy was thenperformed.
A, Preoperative fundus photographdemonstrating white vitreous deposits. B, Postoperative fundus photographof the peripheral retina demonstrating yellow deposits under the retina.
Histopathologic analysis of the vitreous biopsy specimen showed eosinophiliclobules that stained positively with Congo red (Figure 2A) and demonstrated birefringence when examined under polarizedlight (Figure 2B). These findingswere diagnositic of amyloidosis. Oil-red-O stain was negative for lipids andvon Kossa stain was negative for calcium phosphate salts. Genomic DNA wasthen isolated from peripheral blood, and exons corresponding to the entiretransthyretin protein were amplified by the polymerase chain reaction. DirectDNA sequence analysis of the amplified fragments revealed no mutations inthe entire coding sequence, demonstrating that this patient was homozygousfor wild-type transthyretin. Moreover, single-stranded conformational polymorphismand isoelectric focusing analyses did not show any abnormal patterns for transthyretin.The patient subsequently underwent vitrectomy of the right eye. With 7 yearsof clinical follow-up at this report, she has not developed any signs or symptomsof systemic amyloidosis, although there have been increases in the vitreousdeposits in both eyes.
Histopathologic analysis of thevitreous biopsy specimen. A, Positive staining for eosinophilic lobules withCongo red is evident (original magnification ×250). B, Birefringenceis seen when the specimen is examined under polarized light (original magnification×250).
Amyloidosis is a heterogeneous group of disorders involving the depositionof insoluble fibrillar hyaline aggregates in peripheral tissues. Amyloidosisaffecting the vitreous was first reported in 1953 in individuals with FAP,an autosomal dominant disorder that includes vitreopathy, cardiomyopathy,and peripheral neuropathy.2 In fact, vitreoretinalamyloidosis is thought to be found exclusively in individuals with FAP andassociated universally with mutations in the transthyretin gene. To date,more than 80 such transthyretin mutations have been described.1 Incontrast, systemic amyloidosis can result from a number of distinct amyloiddeposits, including wild-type transthyretin3 aswell as other fibrillar proteins.4
To our knowledge, this is the first case report of vitreoretinal amyloidosisin the absence of transthyretin mutations. In addition, no signs of systemicamyloidosis suggestive of FAP were evident 7 years after the patient's initialpresentation, although we cannot exclude the possibility of a subclinicallevel of amyloid deposition in other tissues.5,6 Thesefindings raise the possibility that isolated vitreoretinal amyloidosis mayrepresent a disorder separate from FAP. We conclude that vitreoretinal amyloidosisencompasses a more heterogeneous group of disorders than has been previouslydescribed.
Corresponding author and reprints: Shizuo Mukai, MD, Department ofOphthalmology, Retina Service, Massachusetts Eye and Ear Infirmary, 243 CharlesSt, Boston, MA 02114 (e-mail: firstname.lastname@example.org).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.